Cargando…
SGLT2 Inhibition in HFpEF. Do We Need More Quantitative and Load Independent Metrics to Understand the Results of the EMPEROR-Preserved Trial?
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8795365/ https://www.ncbi.nlm.nih.gov/pubmed/35097034 http://dx.doi.org/10.3389/fcvm.2021.822968 |
| _version_ | 1784641052464906240 |
|---|---|
| author | Korosoglou, Grigorios Giusca, Sorin Kelle, Sebastian |
| author_facet | Korosoglou, Grigorios Giusca, Sorin Kelle, Sebastian |
| author_sort | Korosoglou, Grigorios |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8795365 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Frontiers Media S.A. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-87953652022-01-29 SGLT2 Inhibition in HFpEF. Do We Need More Quantitative and Load Independent Metrics to Understand the Results of the EMPEROR-Preserved Trial? Korosoglou, Grigorios Giusca, Sorin Kelle, Sebastian Front Cardiovasc Med Cardiovascular Medicine Frontiers Media S.A. 2022-01-14 /pmc/articles/PMC8795365/ /pubmed/35097034 http://dx.doi.org/10.3389/fcvm.2021.822968 Text en Copyright © 2022 Korosoglou, Giusca and Kelle. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| spellingShingle | Cardiovascular Medicine Korosoglou, Grigorios Giusca, Sorin Kelle, Sebastian SGLT2 Inhibition in HFpEF. Do We Need More Quantitative and Load Independent Metrics to Understand the Results of the EMPEROR-Preserved Trial? |
| title | SGLT2 Inhibition in HFpEF. Do We Need More Quantitative and Load Independent Metrics to Understand the Results of the EMPEROR-Preserved Trial? |
| title_full | SGLT2 Inhibition in HFpEF. Do We Need More Quantitative and Load Independent Metrics to Understand the Results of the EMPEROR-Preserved Trial? |
| title_fullStr | SGLT2 Inhibition in HFpEF. Do We Need More Quantitative and Load Independent Metrics to Understand the Results of the EMPEROR-Preserved Trial? |
| title_full_unstemmed | SGLT2 Inhibition in HFpEF. Do We Need More Quantitative and Load Independent Metrics to Understand the Results of the EMPEROR-Preserved Trial? |
| title_short | SGLT2 Inhibition in HFpEF. Do We Need More Quantitative and Load Independent Metrics to Understand the Results of the EMPEROR-Preserved Trial? |
| title_sort | sglt2 inhibition in hfpef. do we need more quantitative and load independent metrics to understand the results of the emperor-preserved trial? |
| topic | Cardiovascular Medicine |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8795365/ https://www.ncbi.nlm.nih.gov/pubmed/35097034 http://dx.doi.org/10.3389/fcvm.2021.822968 |
| work_keys_str_mv | AT korosoglougrigorios sglt2inhibitioninhfpefdoweneedmorequantitativeandloadindependentmetricstounderstandtheresultsoftheemperorpreservedtrial AT giuscasorin sglt2inhibitioninhfpefdoweneedmorequantitativeandloadindependentmetricstounderstandtheresultsoftheemperorpreservedtrial AT kellesebastian sglt2inhibitioninhfpefdoweneedmorequantitativeandloadindependentmetricstounderstandtheresultsoftheemperorpreservedtrial |